CRR9/CLPTM1L regulates cell survival signaling and is required for ras transformation and lung tumorigenesis

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1116-1127

  James, Michael A ^a   Vikis, Haris G ^a   Tate, Everett ^a   Rymaszewski, Amy L ^a   You, Ming ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENES, RAS; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84894226710     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1617     Document Type: Article

References (45)

1. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. A novelgene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun 2001;280:1148-54.
2. James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, et al. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One 2012;7: e36116.
3. Ni Z, Tao K, Chen G, Chen Q, Tang J, Luo X, et al. CLPTM1L is overexpressed in lung cancer and associated with apoptosis. PLoS One 2012;7:e52598.
4. Grad JM, Zeng X-R, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000;12:543-9.
5. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010;466:68-76.
6. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16: 34-44.
7. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687-95.
8. Chen XF, Cai S, Chen QG, Ni ZH, Tang JH, Xu DW, et al. Multiple variants of TERT and CLPTM1L constitute risk factors for lung ade-nocarcinoma. Genet Mol Res 2012;11:370-8.
9. Pande M, Spitz MR, Wu X, Gorlov IP, Chen WV, Amos CI. Novelgenetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis 2011;32:1493-9.
10. Wang S, Wu J, Hu L, Ding C, Kan Y, Shen Y, et al. Common genetic variants in TERT contribute to risk of cervical cancer in a Chinese population. Mol Carcinog 2012;51 Suppl 1:E118-22.
11. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008; 40:1404-6.
12. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008;40:1407-9.
13. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Sol-omon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224-8.
14. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42: 978-84.
15. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009;85:679-91.
16. Zhao Y, Chen G, Song X, Chen H, Mao Y, Lu D. Fine-mapping of a region of chromosome 5p15.33 (TERT-CLPTM1L) suggests a novel locus in TERT and a CLPTM1L haplotype are associated with glioma susceptibility in a Chinese population. Int J Cancer 2012; 131:1569-76.
17. Liu P, Vikis HG, Lu Y, Wang Y, Schwartz AG, Pinney SM, et al. Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiol Biomarkers Prev 2010;19:517-24.
18. Yin J, Li Y, Yin M, Sun J, Liu L, Qin Q, et al. TERT-CLPTM1L polymorphism rs401681 contributes to cancers risk: evidence from a meta-analysis based on 29 publications. PLoS One 2012;7: e50650.
19. Vazquez-Mena O, Medina-Martinez I, Juarez-Torres E, Barron V, Espinosa A, Villegas-Sepulveda N, et al. Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines. PLoS One 2012;7:e32667.
20. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 2008;182:1-11.
21. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboller H, et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet 2012;21:4980-95.
22. McDoniels-Silvers AL, Herzog CR, Tyson FL, Malkinson AM, You M. Inactivation of both Rb and p53 pathways in mouse lung epithelial cell lines. Exp Lung Res 2001;27:297-318.
23. Herzog CR, Soloff EV, McDoniels AL, Tyson FL, Malkinson AM, Hau-gen-Strano A, et al. Homozygous codeletion and differential decreased expression of p15INK4b, p16INK4a-alpha and p16INK4a-beta in mouse lung tumor cells. Oncogene 1996;13:1885-91.
24. Chaparro J, Reeds DN, Wen W, Xueping E, Klein S, Semenkovich CF, et al. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism 2005;54:561-7.
25. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
26. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009;4:1064-72.
27. Grundberg E, Small KS, Hedman AK, Nica AC, Buil A, Keildson S, et al. Mapping cis-and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012;44:1084-9.
28. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60: 6750-6.
29. Chen CH, Chen RJ. Prevalence of telomerase activity in human cancer. J Formos Med Assoc 2011;110:275-89.
30. Scherf DB, Sarkisyan N, Jacobsson H, Claus R, Bermejo JL, Peil B, et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene 2013; 32:3329-38.
31. Mirabello L, Yu K, Kraft P, De Vivo I, Hunter DJ, Prescott J, et al. The association of telomere length and genetic variation in telomere biology genes. Hum Mutat 2010;31:1050-8.
32. Pooley KA, Tyrer J, Shah M, Driver KE, Leyland J, Brown J, et al
33. Fehringer G, Liu G, Pintilie M, Sykes J, Cheng D, Liu N, et al. Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumour tissue. Cancer Epidemiol Biomarkers Prev 2012;21:1097-104.
34. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009;41:221-7.
35. Rosen K, Rak J, Leung T, Dean NM, Kerbel RS, Filmus J. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol 2000;149: 447-56.
36. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005;8:381-92.
37. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104-7.
38. Koci L, Hyzd'alova M, Vaculova A, Hofmanova J, Kozubik A. Detachment-mediated resistance to TRAIL-induced apoptosis is associated with stimulation of the PI3K/Akt pathway in fetal and adenocarcinoma epithelial colon cells. Cytokine 2011;55:34-9.
39. Liu SG, Wang BS, Jiang YY, Zhang TT, Shi ZZ, Yang Y, et al. Atypical protein kinase Ciota (PKCiota) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCiota-SKP2-AKT pathway. Mol Cancer Res 2011;9:390-402.
40. Du XL, Yang H, Liu SG, Luo ML, Hao JJ, Zhang Y, et al. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene 2009;28:3714-22.
41. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277:5484-9.
42. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27:462-7.
43. Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gon-zalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3-and Bim-dependent mechanism. Cancer Res 2013;73:1340-51.
44. Lei X, Huang Z, Zhong M, Zhu B, Tang S, Liao D. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adeno-carcinoma cells. Acta Biochim Biophys Sin (Shanghai) 2007;39: 344-50.
45. Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, Houlston R, et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis 2009;30:1368-71.